Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 2/12/2016 5:54:02 PM - Followers: 147 - Board type: Free - Posts Today: 1

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Amended Statement of Ownership (sc 13g/a) 02/12/2016 04:34:46 PM
#3218   New SEC filing after hours today Broadfin capital Inoviorulez 02/12/16 05:54:02 PM
#3217   Not sure that would be $70-160 mil which million_dollar_mafia 02/11/16 05:55:20 PM
#3216   Very plausible considering the short interest curve. Someone The Other Guy 02/11/16 09:19:55 AM
#3215   I have a feeling RXII will have the Titan V 02/10/16 11:48:01 PM
#3214   Buyout coming one day you'll wake up to million_dollar_mafia 02/10/16 10:24:30 PM
#3213   Short interest as of 1/29 is down 800k The Other Guy 02/10/16 03:14:48 PM
#3212   he is trying to get something signed, we Inoviorulez 02/09/16 09:07:04 PM
#3211   Anticipating some interesting outcomes of the MirImmune licensing. The Other Guy 02/09/16 02:54:36 PM
#3210   Makes sense. Now even more pressure for RXI The Other Guy 02/09/16 12:05:16 PM
#3209   Based on more reading and SEC Rule 144, InternetForumUser 02/09/16 11:30:49 AM
#3208   Understood, thanks. Titan V 02/09/16 10:13:34 AM
#3207   RXi Pharmaceuticals to Present at the 18th Annual The Other Guy 02/09/16 09:38:58 AM
#3206   I agree with both recent posts. It could The Other Guy 02/09/16 09:31:05 AM
#3205   The one thing I would be very confident nsomniyak 02/09/16 09:25:37 AM
#3204   It might allow them to make a less nsomniyak 02/09/16 09:23:47 AM
#3203   The other issue with sitting on 4.9% is The Other Guy 02/09/16 09:01:57 AM
#3202   Any ideas? Seems like mm manipulation and shorters million_dollar_mafia 02/08/16 11:25:01 PM
#3201   Actually, Titan, even if they own over 5% nsomniyak 02/08/16 07:59:24 PM
#3200   IMO they are so-so confident with RXII at Titan V 02/08/16 06:06:54 PM
#3199   Titan, that is the other side I was InternetForumUser 02/08/16 06:00:45 PM
#3198   It should be viewed from both directions. I Titan V 02/08/16 05:57:35 PM
#3197   What do you think is happening? I do InternetForumUser 02/08/16 05:40:16 PM
#3196   Interesting hypothesis nsomniyak 02/08/16 09:19:20 AM
#3195   Good observation. The Other Guy 02/08/16 08:56:41 AM
#3194   All funds are bringing their shares down to Inoviorulez 02/07/16 08:40:25 PM
#3193   Well if he is buying then he knows million_dollar_mafia 02/06/16 12:20:00 AM
#3192 comatose 02/05/16 11:37:54 PM
#3191   Although it's not labeled under Anson Capital, comatose 02/05/16 11:18:42 PM
#3190   I can't find anything on them. Will you share? million_dollar_mafia 02/05/16 11:13:47 PM
#3189   FYI those in that filing are from Anson comatose 02/05/16 05:46:07 PM
#3188   New 13G/A filed. 3.3 M shares. The Other Guy 02/05/16 05:04:10 PM
#3187   At the rate RXII volume is recently, the The Other Guy 02/04/16 02:58:22 PM
#3186   Low volume and little interest until a partnership nears. The Other Guy 02/03/16 11:52:07 AM
#3185   Yep, we need something. This $19M valuation is ridiculous. The Other Guy 02/02/16 02:00:23 PM
#3184   We need partnership news or something else. million_dollar_mafia 02/01/16 05:28:22 PM
#3183   Not sure if this has been posted yet: MARLBOROUGH, The Other Guy 01/31/16 09:17:37 PM
#3182   Sometimes hedge funds have ears on the ground The Other Guy 01/30/16 11:00:30 AM
#3181   Yah short interest is down, but we need Inoviorulez 01/29/16 07:59:24 PM
#3180   Short interest down 400k as of 1/15 reporting The Other Guy 01/29/16 12:09:24 PM
#3179   I'm sure potential partners are using the threat The Other Guy 01/25/16 09:49:30 PM
#3178   This company will need to release some stellar Inoviorulez 01/25/16 06:46:19 PM
#3177   We know where volume has come from. Nothing The Other Guy 01/20/16 10:11:02 AM
#3176   That is too bad, now that is two InternetForumUser 01/19/16 09:34:30 PM
#3175   Checking at looks like it is a Titan V 01/19/16 08:59:47 PM
#3174 Is Empery decreasing stake Titan V 01/19/16 07:54:53 PM
#3173   Schedule 13g filed The Other Guy 01/19/16 07:29:18 PM
#3172   Boy o boy million_dollar_mafia 01/15/16 01:56:11 PM
#3171   Yeah, this is tiring. Market values the company The Other Guy 01/13/16 04:44:05 PM
#3170   It sucks but it's all over the sector Titan V 01/13/16 04:42:50 PM
#3169   Another drop in the PPS. InternetForumUser 01/13/16 04:24:30 PM